Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Debt to Equity (2016 - 2025)

Amphastar Pharmaceuticals has reported Debt to Equity over the past 13 years, most recently at $0.77 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.77 for Q4 2025, down 5.85% from a year ago — trailing twelve months through Dec 2025 was $0.77 (down 5.85% YoY), and the annual figure for FY2025 was $0.77, down 5.85%.
  • Debt to Equity for Q4 2025 was $0.77 at Amphastar Pharmaceuticals, down from $0.78 in the prior quarter.
  • Over the last five years, Debt to Equity for AMPH hit a ceiling of $1.07 in Q3 2023 and a floor of $0.08 in Q2 2021.
  • Median Debt to Equity over the past 5 years was $0.78 (2025), compared with a mean of $0.53.
  • Biggest five-year swings in Debt to Equity: soared 616.19% in 2023 and later dropped 23.58% in 2024.
  • Amphastar Pharmaceuticals' Debt to Equity stood at $0.17 in 2021, then dropped by 16.92% to $0.14 in 2022, then soared by 542.83% to $0.92 in 2023, then decreased by 10.93% to $0.82 in 2024, then fell by 5.85% to $0.77 in 2025.
  • The last three reported values for Debt to Equity were $0.77 (Q4 2025), $0.78 (Q3 2025), and $0.8 (Q2 2025) per Business Quant data.